Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery

INTRODUCTION: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been suff...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallmeier, Eike, Bader, Dominik C., Kriegl, Lydia, Berezowska, Sabina, Seeliger, Hendrik, Göke, Burkhard, Kirchner, Thomas, Bruns, Christiane, De Toni, Enrico N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584093/
https://www.ncbi.nlm.nih.gov/pubmed/23460812
http://dx.doi.org/10.1371/journal.pone.0056760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584093/
https://www.ncbi.nlm.nih.gov/pubmed/23460812
http://dx.doi.org/10.1371/journal.pone.0056760

Ejemplares similares